DalsnaFinance Account

Cencora $COR

Health Care · Health Care Distributors · NYSE/NASDAQ

S&P 500 Russell 1000 Pennsylvania

Create a scorecard

$343.27

+3.27 (+0.96%)

As of Oct 20, 2026, 7:36 PM EDT

Price history

Loading chart…

Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Sep 8, 2026, the first target we tracked for COR.

Key facts

52-week range (closes): $252.74 – $374.75 Lowest close May 6, 2026, highest Nov 25, 2025; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
Fiscal year ends: September Fiscal 2025 ended Sep 30, 2025, from SEC filings
In the S&P 500 since: Aug 30, 2001 · All S&P 500 changes
Analyst coverage: 1 open price target from 1 firm: RBC Capital Markets Approved targets tracked here; see the analyst section below

Cencora (COR) is trading up at $343.27 (+0.96%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Analyst price targets on COR

One firm's current price target on Cencora: $330 — 4% below the current $343. Each is tracked to its date and scored the same way a member's call is.

RBC Capital Markets $325 → $330 by Sep 2027 Sector Perform Sep 8, 2026 via Investing.com · RBC Capital Markets's track record

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Cencora revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)

Cencora annual financial statements
	FY2016Sep 2016	FY2017Sep 2017	FY2018Sep 2018	FY2019Sep 2019	FY2020Sep 2020	FY2021Sep 2021	FY2022Sep 2022	FY2023Sep 2023	FY2024Sep 2024	FY2025Sep 2025
Income statement
Revenue	$146.8B	$153.1B	$167.9B	$179.6B	$189.9B	$214.0B	$238.6B	$262.2B	$294.0B	$321.3B
Growth (year over year)	+8.0%	+4.3%	+9.7%	+6.9%	+5.7%	+12.7%	+11.5%	+9.9%	+12.1%	+9.3%
Gross profit	$4.27B	$4.55B	$4.61B	$5.14B	$5.19B	$6.94B	$8.30B	$8.96B	$9.91B	$11.5B
Gross margin	2.9%	3.0%	2.7%	2.9%	2.7%	3.2%	3.5%	3.4%	3.4%	3.6%
Operating income	$1.53B	$1.06B	$1.44B	$1.11B	−$5.14B	$2.35B	$2.37B	$2.34B	$2.18B	$2.63B
Operating margin	1.0%	0.7%	0.9%	0.6%	−2.7%	1.1%	1.0%	0.9%	0.7%	0.8%
Net income	$1.43B	$364.5M	$1.66B	$855.4M	−$3.41B	$1.54B	$1.70B	$1.75B	$1.51B	$1.55B
Net margin	1.0%	0.2%	1.0%	0.5%	−1.8%	0.7%	0.7%	0.7%	0.5%	0.5%
EPS (diluted)	$6.32	$1.64	$7.53	$4.04	−$16.65	$7.39	$8.04	$8.53	$7.53	$7.96
Balance sheet
Cash and equivalents	$2.74B	$2.44B	$2.49B	$3.37B	$4.60B	$2.55B	$3.39B	$2.59B	$3.13B	$4.36B
Total assets	$33.6B	$35.3B	$37.7B	$39.2B	$44.3B	$57.3B	$56.6B	$62.6B	$67.1B	$76.6B
Total liabilities	$31.5B	$33.3B	$34.6B	$36.2B	$45.1B	$56.8B	$56.5B	$61.9B	$66.3B	$74.8B
Long-term debt	$3.58B	$3.43B	$4.16B	$4.03B	$3.62B	$6.38B	$4.63B	$4.15B	$3.81B	$7.54B
Shareholders' equity	$2.13B	$2.06B	$2.93B	$2.88B	−$1.02B	$223.4M	−$211.6M	$522.0M	$645.9M	$1.51B
Cash flow
Operating cash flow	$3.18B	$1.50B	$1.41B	$2.34B	$2.21B	$2.67B	$2.70B	$3.91B	$3.48B	$3.88B
Capital expenditure	$464.6M	$466.4M	$336.4M	$310.2M	$369.7M	$438.2M	$496.3M	$458.4M	$487.2M	$668.0M
Free cash flow	$2.71B	$1.04B	$1.07B	$2.03B	$1.84B	$2.23B	$2.21B	$3.45B	$3.00B	$3.21B
Dividends paid	$288.5M	$320.3M	$333.0M	$339.0M	$343.6M	$366.6M	$391.7M	$398.8M	$416.2M	$437.1M
Share buybacks	$2.27B	$329.9M	$639.2M	$674.0M	$420.4M	$82.2M	$483.7M	$1.18B	$1.49B	$435.5M

RevenueNet incomeNet margin (right axis, %)

Cencora quarterly financial statements
	Q4 FY24^†Sep 2024	Q1 FY25Dec 2024	Q2 FY25Mar 2025	Q3 FY25Jun 2025	Q4 FY25^†Sep 2025	Q1 FY26Dec 2025	Q2 FY26Mar 2026	Q3 FY26Jun 2026
Income statement
Revenue	$79.1B	$81.5B	$75.5B	$80.7B	$83.7B	$85.9B	$78.4B	$84.8B
Growth (year over year)	+14.7%	+12.8%	+10.3%	+8.7%	+5.9%	+5.5%	+3.8%	+5.1%
Gross profit	$2.49B	$2.56B	$3.06B	$2.91B	$2.95B	$3.07B	$3.59B	$3.61B
Gross margin	3.2%	3.1%	4.1%	3.6%	3.5%	3.6%	4.6%	4.3%
Operating income	$126.6M	$706.3M	$1.04B	$867.7M	$18.5M	$760.4M	$1.14B	$1.12B
Operating margin	0.2%	0.9%	1.4%	1.1%	0.0%	0.9%	1.5%	1.3%
Net income	$3.38M	$488.6M	$717.9M	$687.4M	−$339.7M	$559.6M	$1.64B	$763.5M
Net margin	0.0%	0.6%	1.0%	0.9%	−0.4%	0.7%	2.1%	0.9%
EPS (diluted)	$0.04	$2.50	$3.68	$3.52	−$1.74	$2.87	$8.40	$3.94
Balance sheet
Cash and equivalents	$3.13B	$3.22B	$1.98B	$2.23B	$4.36B	$1.75B	$2.18B	$2.82B
Total assets	$67.1B	$69.1B	$71.2B	$74.0B	$76.6B	$78.4B	$81.7B	$83.8B
Total liabilities	$66.3B	$68.7B	$70.0B	$71.7B	$74.8B	$76.3B	$78.1B	$80.6B
Long-term debt	$3.81B	$5.94B	$7.09B	$8.04B	$7.54B	$7.58B	$12.2B	$11.4B
Shareholders' equity	$645.9M	$226.6M	$1.01B	$1.98B	$1.51B	$1.91B	$3.40B	$3.05B
Cash flow
Operating cash flow	$1.00B	−$2.72B	$3.35B	$109.2M	$3.13B	−$2.31B	$1.34B	$2.65B
Capital expenditure	$182.3M	$105.9M	$129.1M	$183.2M	$249.8M	$119.4M	$165.6M	$226.0M
Free cash flow	$818.1M	−$2.82B	$3.22B	−$74.0M	$2.88B	−$2.42B	$1.17B	$2.43B
Dividends paid	$100.9M	$110.9M	$111.2M	$107.5M	$107.5M	$126.5M	$117.5M	$116.6M
Share buybacks	$505.0M	$385.4M	$50.0M	$0	$71.0K	—	—	—

From Cencora's 10-K and 10-Q filings with the SEC; its fiscal year ends in September. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Cencora vs the Health Care sector and the S&P 500

Cencora's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.

Cencora compared with the median Health Care company and the median S&P 500 company
Measure	Cencora	Health Care (59 other S&P 500 companies)	S&P 500 (502 other companies)
Revenue growth, latest fiscal year	+9.3%	+7.1%	+7.0%
Net margin, latest fiscal year	0.5%	13.1%	13.0%
Dividend per share, latest fiscal year	$2.20	$2.48	$2.40
Share price change, 1 year	+4.9%	+22.8%	+7.5%

Cencora: fiscal year ended September 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Cencora included, are the last regular-session prices of October 20, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, dividend per share 32/349, 1-year price change 59/488; the reasons below can overlap. 14 are left out of the price figure because our archive holds no comparable close for them; dividend medians are among the 32 sector and 349 S&P 500 companies reporting a per-share dividend. The S&P 500 price figure is the middle company's change, not the index's return.

About Cencora

Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale and distribution company and a contract research organization, that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. It was renamed to Cencora in 2023. Cencora is one of the largest pharmaceutical companies in the world and distributes generic pharmaceuticals, over-the-counter healthcare products, as well as home healthcare supplies and equipment. The company is headquartered in Conshohocken, Pennsylvania, part of the Philadelphia metropolitan area.

Source: Wikipedia — Cencora